MARKET WIRE NEWS
  1. Home
  2. Stock
  3. TRDA
  4. News
  5. Entrada Plunges After Early Stage Trial Data For Duc
TRDA
Quote
Short
News
Articles
Message Board

Entrada plunges after early-stage trial data for Duchenne therapy

Source: SeekingAlpha

2026-05-07 10:38:26 ET

More on Entrada Therapeutics

Read the full article on Seeking Alpha

For further details see:

Entrada plunges after early-stage trial data for Duchenne therapy
Entrada Therapeutics Inc.

NASDAQ: TRDA

TRDA Trading

-4.65% G/L:

$6.66 Last:

69,203 Volume:

$6.93 Open:

mwn-alerts Ad 300

TRDA Latest News

June 02, 2026 07:00:00 am
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
May 08, 2026 03:15:03 pm
TRDA Price Target Alert: $10.00. Issued by Roth Capital
May 07, 2026 07:10:00 am
Entrada Therapeutics Reports First Quarter 2026 Financial Results
May 07, 2026 07:00:00 am
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

TRDA Stock Data

$413,532,090
18,654,807
28.07%
31
N/A
Biotechnology & Life Sciences
Healthcare
https://www.entradatx.com
US
Boston

Subscribe to Our Newsletter

Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.

Link Market Wire News to Your X Account

Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.

Download The Market Wire News App

Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.

Market Wire News iPhone App Market Wire News Android App